Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Botulinum Toxin Type A and B Benefits to Change for Texas Medicaid, Effective September 1, 2020

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to eligible clients. Administrative procedures such as prior authorization, pre-certification, referrals, and claims/encounter data filing may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the client's specific MCO for details.

Effective September 1, 2020, botulinum toxin type A and B benefits for Texas Medicaid will be updated to allow reimbursement for the amount discarded (unused). Providers must include modifier JW on a separate claim line for consideration of reimbursement for the unused portion of single-dose vials.

Providers may refer to the current Texas Medicaid Provider Procedures Manual, Clinician-Administered Drugs Handbook, subsection 4, “Reimbursement,” for additional information about reimbursement for the unused portion of weight-based or variable dosing clinician-administered drugs that are only manufactured in single-dose vials.

For more information, call the TMHP Contact Center at 800-925-9126.